Skip to main content
SpringerLink
Log in

Beendigung einer Therapie mit Antipsychotika und Antidepressiva

Entstehung, Merkmale, Prävention und Behandlung von Absetzphänomenen

  • Zertifizierte Fortbildung Psychiatrie
  • Published:
InFo Neurologie + Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Schwabe U, Paffrath D, Ludwig WD, Klauber J. Arzneiverordnungs-Report 2019

  2. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Brit J Psychiatry 1997; 170: 120-7

    Article  CAS  PubMed  Google Scholar 

  3. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23

    Article  CAS  PubMed  Google Scholar 

  4. Cerovecki A, Musil R, Klimke A, Seemüller F, Haen E, Schennach R et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: Theoretical background and practical recommendations. CNS Drugs 2013; 27: 545-72

    Article  CAS  PubMed  Google Scholar 

  5. Brooks GW. Withdrawal from neuroleptic drugs. Am J Psychiatr. 1959; 115: 931-2

    Article  CAS  PubMed  Google Scholar 

  6. Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. BPS 1984; 19: 237-56

  7. Hollister LE, Eikenberry DT, Raffel S. Chlorpromazine in nonpsychotic patients with pulmonary tuberculosis. Am Rev Respir Dis 1960; 81: 562-6

  8. Chouinard G, Samaha A-N, Chouinard V-A, Peretti C-S, Kanahara N, Takase M et al. Antipsychotic-induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom 2017; 86: 189-219

    Article  PubMed  Google Scholar 

  9. Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Dementia and Cognitive Improvement Group, editor. Cochrane Database of Systematic Reviews 2018; 65: 114

  10. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant withdrawal and rebound Phenomena. Dtsch Arztebl Int 2019; 116: 355-61

  11. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective Serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom 2015; 84: 72-81

    Article  PubMed  Google Scholar 

  12. Heinz A, Daedelow L, Wackerhagen L, Di Chiara G. Addiction theory matters - why there is no dependence on caffeine or antidepressant medication (in press). Addiction Biology 2019; 1-10

  13. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN) (Hrsg.) S3-Leitlinie Schizophrenie AWMF-Register Nr. 038-009 Leitlinienreport Stand: 15.03.2019

  14. Geffen E, Brugman M, Hulten R, Bouvy ML, Egberts A, Heerdink ER. Patients' concerns about and problems experienced with discontinuation of antidepressants. Int J Pharmacy Practice 2007; 15: 291-3

    Article  Google Scholar 

  15. Lader M. Benzodiazepine withdrawal states. In: Trimble M R (ed.), Benzodiazepines divided. New York: John Wiley; 1983

  16. Falkai P, Wittchen HU. Diagnostisches und statistisches Manual psychischer Störungen: DSM-5. 2015

  17. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. BPS 1998; 44: 77-87

    Article  CAS  PubMed  Google Scholar 

  18. Berber MJ. FINISH: remembering the discontinuation syndrome. Flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal (anxiety/agitation). J Clin Psychiatry 1998; 59: 255

    Article  CAS  PubMed  Google Scholar 

  19. Benmansour S, Altamirano AV, Jones DJ, Sanchez TA, Gould GG, Pardon M-C et al. Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biological Psychiatry 2004; 55: 313-6

    Article  CAS  PubMed  Google Scholar 

  20. Kittler K, Lau T, Schloss P. Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharmacology 2010; 629: 63-7

    Article  CAS  PubMed  Google Scholar 

  21. Mirza NR, Nielsen EØ, Troelsen KB. Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 858-66

    Article  CAS  PubMed  Google Scholar 

  22. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A. Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci; 22: 6766-72

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Klomp A, Hamelink R, Feenstra M, Denys D, Reneman L. Increased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brain. PLoS ONE 2014; 9: e99873-10

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Reidenberg MM. Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 2011; 339: 324-8

    Article  CAS  PubMed  Google Scholar 

  25. Dilling H, Freyberger HJ. Taschenführer zur ICD-10-Klassifikation psychischer Störungen. Göttingen, Germany: Hogrefe 2013

  26. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007; 27: 2979-86

    Article  CAS  PubMed  Google Scholar 

  27. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S. Less is more: Antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 2008; 64: 145-52

    Article  CAS  PubMed  Google Scholar 

  28. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology 2000; 152: 174-80

    Article  CAS  PubMed  Google Scholar 

  29. Leucht S, Davis JM. Do antipsychotic drugs lose their efficacy for relapse prevention over time? Br J Psychiatry 2017; 211: 127-9

    Article  PubMed  Google Scholar 

  30. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-71

    Article  CAS  Google Scholar 

  31. Takeuchi H, Kantor N, Sanches M, Fervaha G, Agid O, Remington G. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis. Br J Psychiatry 2017; 211: 137-43

    Article  PubMed  Google Scholar 

  32. Taylor MJ, Yim S. Is there rebound psychosis on withdrawal of antipsychotic medication in schizophrenia? Schizophrenia Res 2018; 1-2

  33. El-Mallakh RS, Briscoe B. Studies of long-term use of antidepressants: how should the data from them be interpreted? CNS Drugs 2012; 26: 97-109

    Article  CAS  PubMed  Google Scholar 

  34. Lacoursiere RB, Spohn HE, Thompson K. Medical effects of abrupt neuroleptic withdrawal. Comprehensive Psychiatry 1976; 17: 285-94

    Article  CAS  PubMed  Google Scholar 

  35. Tranter R, Healy D. Neuroleptic discontinuation syndromes. J Psychopharmacol 1998; 12: 401-6

    Article  CAS  PubMed  Google Scholar 

  36. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom 2015; 84: 72-81

    Article  PubMed  Google Scholar 

  37. Chouinard G, Chouinard V-A. New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63-71

    Article  PubMed  Google Scholar 

  38. Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89: 207-12

    Article  CAS  PubMed  Google Scholar 

  39. Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2005; 10: 73-12

    Article  PubMed  CAS  Google Scholar 

  40. Markowitz JS, DeVane CL, Liston HL, Montgomery SA. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000; 15: 329-33

    Article  CAS  PubMed  Google Scholar 

  41. Greenberg LM, Roth S. Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. Am J Psychiatry 1966; 123: 221-6

    Article  CAS  PubMed  Google Scholar 

  42. Emsley R, Nuamah I, Gopal S, Hough D, Fleischhacker WW. Relapse after antipsychotic discontinuation in schizophrenia as a withdrawal phenomenon vs illness recurrence: A post hoc analysis of a randomized placebo-controlled study. J Clin Psychiatry 2018; 79

  43. DGPPN, BÄK, KBV, AWMF. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage. Version 5; 2017

  44. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry 2019; 6: 538-46

    Article  PubMed  Google Scholar 

  45. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994; 14: 206-7

    Article  CAS  PubMed  Google Scholar 

  46. Benazzi F. Fluoxetine for the treatment of SSRI discontinuation syndrome. Int J Neuropsychopharmacol 2008; 11: 27-2

  47. Giakas WJ, Davis JM. Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatric Annals 1997; 27: 85-92

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Psychiatrische Universitätsklinik der Charité im St. Hedwig-Krankenhaus, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    Lasse Brandt, Jonathan Henssler & Stefan Gutwinski

Authors
  1. Lasse Brandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Henssler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Gutwinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen und im Zusammenhang mit diesem Beitrag keine Interessenkonflikte bestehen.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brandt, L., Henssler, J. & Gutwinski, S. Entstehung, Merkmale, Prävention und Behandlung von Absetzphänomenen. InFo Neurologie 22, 26–35 (2020). https://doi.org/10.1007/s15005-020-1293-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-020-1293-6

Search

Navigation